Logo do repositório
 
Publicação

Mecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABL

2013-07Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorGomes da Silva, Maria
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblBiblioteca Nacional de Portugal, Centro de Estudos Históricos, CELOM
dc.date.accessioned2017-06-21T22:00:39Z
dc.date.available2017-06-21T22:00:39Z
dc.date.issued2013-07
dc.description.abstractSince the introduction of imatinib mesylate for the treatment of chronic myeloid leukaemia, impressive clinical responses were observed in the majority of patients in chronic phase. However, not all patients experience an optimal response to imatinib mesylate or even to the more potent, second generation tyrosine kinase inhibitors. Furthermore, responses are not sustained in a number of patients, and it is yet unclear whether the inhibitors can be safely discontinued in patients who achieve long-term remission. The emergence of resistance to second generation tyrosine kinase inhibitors has become a significant problem that led to extensive studies on the causal mechanisms. This review will describe our current state of knowledge on why and how chronic myeloid leukaemia cells can develop resistance to second generation tyrosine kinase inhibitors.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent7
dc.format.extent370853
dc.identifier.issn1646-0758
dc.identifier.otherPURE: 236033
dc.identifier.otherPURE UUID: c0309320-a07b-4136-8ec8-494cf5cac4ac
dc.identifier.otherresearchoutputwizard: 40087
dc.identifier.otherPubMed: 24016650
dc.identifier.otherWOS: 000327479900019
dc.identifier.otherScopus: 84883526760
dc.identifier.urihttp://hdl.handle.net/10362/21638
dc.language.isopor
dc.peerreviewedyes
dc.subjectIMATINIB MESYLATE
dc.subjectCML CELLS
dc.subjectCHRONIC MYELOID-LEUKEMIA
dc.subjectPHILADELPHIA-POSITIVE PATIENTS
dc.subjectDrug Resistance, Neoplasm
dc.subjectSTEM-CELLS
dc.subjectProtein Kinase Inhibitors
dc.subjectDOMAIN MUTATIONS
dc.subjectImatinib
dc.subjectLOW OCT-1 ACTIVITY
dc.subjectTYROSINE KINASE
dc.subjectACUTE LYMPHOBLASTIC-LEUKEMIA
dc.subjectCHRONIC MYELOGENOUS LEUKEMIA
dc.subjectLeukemia, Myelogenous, Chronic, BCR-ABL Positive
dc.titleMecanismos de Resistência aos Inibidores da Tirosina Cinase BCR-ABLpt
dc.title.alternativeMechanisms of Resistance to BCR-ABL Kinase Inhibitorsen
dc.typejournal article
degois.publication.firstPage402
degois.publication.issue4
degois.publication.lastPage408
degois.publication.titleActa Médica Portuguesa
degois.publication.volume26
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
4812-6587-1-SM.pdf
Tamanho:
362.16 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista nacional com arbitragem científica